A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a self-administered lupus drug was turned back and MeiraGTx picked up another gene ...

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...

Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...

A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...

The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...

The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...

A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...